Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that it is broadening its partnership with Medochemie, a Cyprus-based pharma company to manufacture its innovative products in Vietnam and improve patient access to high-quality locally manufactured medicines. Under this partnership, Viatris will transfer technology that will license Medochemie to manufacture Viatris’ identified NCD products, in its Vietnam facilities.
The partnership with Medochemie is intended to further fuel our efforts to support the Vietnam Government’s goal to enable technology transfer for strengthening local manufacturing capabilities and helping achieve the vision of making Vietnam the ASEAN hub for pharmaceutical manufacturing in the next 10 – 20 years.
Ms. Yun Ju Eunice Jo, Country Manager, Viatris Vietnam, commented: “Our relentless pursuit is to improve access to high-quality trusted medicines and empowering people worldwide to live healthier at every stage of life. Our partnership with Medochemie is yet another milestone in our localization efforts and our commitment to further expand access to quality medicines to the people in Vietnam. We will continue to work and support the Government’s vision to foster access to quality medicine through local manufacturing.”
Dr. Daphne Pittas, Board Member and Chief Operations Officer, Medochemie Ltd, noted: “The partnership provides motivation to the local pharmaceutical industry’s capabilities in manufacturing high quality medicines such as complex solid dosage forms and injectable lifesaving antibiotics.” She added: “Medochemie strongly believes in and will continue to support the scientific and technological advancement of the pharmaceutical sector in Vietnam, being an active member in the country’s industrial network and seeking to develop valued collaborations, such as this one.”
As part of this partnership, Viatris and Medochemie will support the Government’s vision for localization and manufacture of high-quality medicines in Vietnam.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
Medochemie Group was founded in 1976 by Dr. Andreas Pittas, with headquarters in Limassol, Cyprus, operating 15 manufacturing plants and facilities, 10 in Europe and 5 in Vietnam. With over 1,600 employees, the company has implemented the strictest quality standards, in full compliance with European guidelines for all facilities. In 46 years of operations, Medochemie has expanded its business into markets around the world and today exports globally. A network of offices and partners has been developed in 107 countries, from Europe, the Middle East, Africa, through to Southeast Asia and America, having its own offices in 22 countries. Medochemie’s mission is to provide quality drug treatment at affordable prices to all people across the globe. Medochemie Group has invested in the development of two high technology projects in Vietnam under the name Medochemie (Far East), consisting of 5 production facilities and 9 different production lines from solid dosage forms to sterile powders for injection.